Rhythm Pharmaceuticals jumps as investors focus on FDA decision timing for hypothalamic obesity label expansion

Rhythm Pharmaceuticals, Inc. (RYTM) is up 3.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to heightened investor positioning around the FDA’s March 20, 2026 PDUFA goal date for IMCIVREE (setmelanotide) in acquired hypothalamic obesity, following recently released Phase 3 data and company updates on its regulatory timeline. In the absence of a clearly disseminated, single intraday headline, the most likely driver is event-driven trading into the regulatory catalyst.

Details:

Rhythm has highlighted a March 20, 2026 PDUFA goal date for its supplemental NDA seeking an IMCIVREE label expansion for conditions associated with acquired hypothalamic obesity.

The company previously stated it would submit a final supplemental data package to the FDA in early March 2026, ahead of the agreed submission timing, keeping attention on a near-term decision.

Rhythm recently shared additional Phase 3 TRANSCEND data in acquired hypothalamic obesity, reinforcing the efficacy narrative that underpins the pending label expansion.

In its late-February business update, the company reiterated the upcoming FDA milestone and discussed launch preparations contingent on approval, which can amplify pre-decision volatility.

Sources:

GlobeNewswire, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RYTM Insider Trading Activity

$RYTM insiders have traded $RYTM stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.

Here’s a breakdown of recent trading of $RYTM stock by insiders over the last 6 months:

JOSEPH SHULMAN (Chief Technical Officer) has made 0 purchases and 5 sales selling 27,000 shares for an estimated $3,064,484.
PAMELA J. CRAMER (Chief Human Resources Officer) has made 0 purchases and 4 sales selling 29,566 shares for an estimated $2,987,425.
HUNTER C SMITH (Chief Financial Officer) has made 0 purchases and 23 sales selling 21,653 shares for an estimated $2,217,133.
CHRISTOPHER PAUL GERMAN (Corporate Controller & CAO) sold 5,614 shares for an estimated $502,789

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$RYTM Hedge Fund Activity

We have seen 154 institutional investors add shares of $RYTM stock to their portfolio, and 144 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VANGUARD GROUP INC added 1,214,489 shares (+24.3%) to their portfolio in Q4 2025, for an estimated $129,998,902
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,200,868 shares (-68.6%) from their portfolio in Q4 2025, for an estimated $128,540,910
ALKEON CAPITAL MANAGEMENT LLC removed 1,017,700 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $108,934,608
RA CAPITAL MANAGEMENT, L.P. added 985,478 shares (+17.3%) to their portfolio in Q4 2025, for an estimated $105,485,565
PRIMECAP MANAGEMENT CO/CA/ removed 784,190 shares (-18.4%) from their portfolio in Q4 2025, for an estimated $83,939,697
JENNISON ASSOCIATES LLC added 507,017 shares (+123.2%) to their portfolio in Q4 2025, for an estimated $54,271,099
ROCKEFELLER CAPITAL MANAGEMENT L.P. added 444,029 shares (+5007.1%) to their portfolio in Q4 2025, for an estimated $47,528,864

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$RYTM Analyst Ratings

Wall Street analysts have issued reports on $RYTM in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 02/26/2026
HC Wainwright & Co. issued a "Buy" rating on 01/20/2026
Guggenheim issued a "Buy" rating on 12/17/2025
Citizens issued a "Market Outperform" rating on 12/12/2025
Citigroup issued a "Buy" rating on 11/25/2025
Canaccord Genuity issued a "Buy" rating on 11/10/2025
Goldman Sachs issued a "Buy" rating on 10/17/2025

To track analyst ratings and price targets for $RYTM, check out Quiver Quantitative's $RYTM forecast page.

$RYTM Price Targets

Multiple analysts have issued price targets for $RYTM recently. We have seen 12 analysts offer price targets for $RYTM in the last 6 months, with a median target of $139.5.

Here are some recent targets:

Jonathan Wolleben from Citizens set a target price of $155.0 on 03/20/2026
Raghuram Selvaraju from HC Wainwright & Co. set a target price of $100.0 on 03/18/2026
Tazeen Ahmad from B of A Securities set a target price of $139.0 on 03/17/2026
Jeffrey Hung from Morgan Stanley set a target price of $136.0 on 03/17/2026
Samantha Semenkow from Citigroup set a target price of $131.0 on 03/17/2026
Lisa Walter from RBC Capital set a target price of $130.0 on 03/17/2026
Joseph Stringer from Needham set a target price of $130.0 on 03/17/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.